Literature DB >> 16635427

Paraneoplastic neurologic syndromes.

Steven Vernino1.   

Abstract

Paraneoplastic neurologic disorders (PND) are remote medical complications of cancer that cannot be attributed to direct effects of the neoplasm or its metastases. PND are uncommon, disabling syndromes that have been recognized for more than 50 years. Despite their rarity, these diseases are the subject of intensive research and clinical fascination. This review highlights notable recent publications related to PND. In recent years, the broad clinical spectrum of PND has become even more apparent. PND can affect any part of the central or peripheral nervous system and often affect multiple areas simultaneously. These disorders are often associated with neuron-specific autoantibodies in the serum and cerebrospinal fluid. In clinical practice, detection of these antibodies is crucial for the diagnosis because the neurologic symptoms usually precede the diagnosis of cancer. Recent publications have described new antibody specificities associated with PND and expand our ability to identify patients serologically. Once diagnosed, detection of cancer can be difficult, but the use of positron emission tomography has been shown to be a useful supplement to standard imaging procedures. PND are thought to be autoimmune disorders precipitated by the immune response to cancer. Observations and laboratory studies in PND patients have shown that activation of cytotoxic T cells is an important component of the disease. These studies not only shed light on the pathogenesis of PND and the mechanisms of effective antitumor immunity but may eventually lead to improved treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16635427     DOI: 10.1007/s11910-006-0005-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  50 in total

1.  Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor.

Authors:  P Sillevis Smitt; A Kinoshita; B De Leeuw; W Moll; M Coesmans; D Jaarsma; S Henzen-Logmans; C Vecht; C De Zeeuw; N Sekiyama; S Nakanishi; R Shigemoto
Journal:  N Engl J Med       Date:  2000-01-06       Impact factor: 91.245

Review 2.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

3.  Ulip/CRMP proteins are recognized by autoantibodies in paraneoplastic neurological syndromes.

Authors:  J Honnorat; T Byk; I Kusters; M Aguera; D Ricard; V Rogemond; T Quach; D Aunis; A Sobel; M G Mattei; P Kolattukudy; M F Belin; J C Antoine
Journal:  Eur J Neurosci       Date:  1999-12       Impact factor: 3.386

4.  Chorea resulting from paraneoplastic striatal encephalitis.

Authors:  T Tani; Y Piao; S Mori; N Ishihara; K Tanaka; K Wakabayashi; H Takahashi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-10       Impact factor: 10.154

5.  A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer.

Authors:  R Voltz; S H Gultekin; M R Rosenfeld; E Gerstner; J Eichen; J B Posner; J Dalmau
Journal:  N Engl J Med       Date:  1999-06-10       Impact factor: 91.245

6.  CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.

Authors:  Z Yu; T J Kryzer; G E Griesmann; K Kim; E E Benarroch; V A Lennon
Journal:  Ann Neurol       Date:  2001-02       Impact factor: 10.422

7.  Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis.

Authors:  Rainer Linke; Mira Schroeder; Thomas Helmberger; Raymond Voltz
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

8.  FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.

Authors:  S Younes-Mhenni; M F Janier; L Cinotti; J C Antoine; F Tronc; V Cottin; P J Ternamian; P Trouillas; J Honnorat
Journal:  Brain       Date:  2004-09-10       Impact factor: 13.501

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Clinical analysis of anti-Ma2-associated encephalitis.

Authors:  Josep Dalmau; Francesc Graus; Alberto Villarejo; Jerome B Posner; Deborah Blumenthal; Brian Thiessen; Albert Saiz; Patricio Meneses; Myrna R Rosenfeld
Journal:  Brain       Date:  2004-06-23       Impact factor: 13.501

View more
  2 in total

1.  Progress in the management of paraneoplastic neurological disorders.

Authors:  Hamid Sadeghian; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

Review 2.  Seizures and epilepsy in cancer: etiologies, evaluation, and management.

Authors:  Jai Grewal; Harpreet K Grewal; Arthur D Forman
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.